NYSE:NVS - Novartis Stock Price, Price Target & More

$76.42 -0.57 (-0.74 %)

(As of 04/25/2018 04:00 PM ET)

Previous Close$76.99

Today's Range$75.73 - $76.56

52-Week Range$75.62 - $94.19

Volume1.29 million shs

Average Volume1.75 million shs

Market Capitalization$179.83 billion

P/E Ratio15.89

Dividend Yield2.46%

Beta0.75

About Novartis (NYSE:NVS)

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; and PEAR Therapeutics. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNYSE:NVS

CUSIPN/A

Webwww.novartis.com

Phone41-61-324-1111

Debt

Debt-to-Equity Ratio0.33%

Current Ratio1.17%

Quick Ratio0.91%

Price-To-Earnings

Trailing P/E Ratio15.89

Forward P/E Ratio14.47

P/E Growth1.74

Sales & Book Value

Annual Sales$49.11 billion

Price / Sales3.61

Cash Flow$7.5291 per share

Price / Cash10.15

Book Value$30.73 per share

Price / Book2.49

Profitability

EPS (Most Recent Fiscal Year)$4.81

Net Income$7.70 billion

Net Margins16.04%

Return on Equity16.23%

Return on Assets8.69%

Miscellaneous

Employees121,597

Outstanding Shares2,317,460,000

How to Become a New Pot Stock Millionaire

Novartis (NYSE:NVS) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How will Novartis' stock buyback program work?

Novartis declared that its Board of Directors has approved a stock buyback program on Saturday, April 8th 2017, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.9% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's management believes its shares are undervalued.

How were Novartis' earnings last quarter?

Novartis (NYSE:NVS) posted its quarterly earnings results on Thursday, April, 19th. The company reported $1.28 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.25 by $0.03. The business had revenue of $12.69 billion for the quarter, compared to the consensus estimate of $12.45 billion. Novartis had a return on equity of 16.23% and a net margin of 16.04%. The business's revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.13 earnings per share. View Novartis' Earnings History.

When is Novartis' next earnings date?

Novartis is scheduled to release their next quarterly earnings announcement on Tuesday, July, 17th 2018. View Earnings Estimates for Novartis.

What price target have analysts set for NVS?

10 brokers have issued 12 month price objectives for Novartis' stock. Their forecasts range from $82.25 to $91.00. On average, they expect Novartis' stock price to reach $87.75 in the next year. View Analyst Ratings for Novartis.

Are investors shorting Novartis?

Novartis saw a drop in short interest during the month of March. As of March 15th, there was short interest totalling 1,430,834 shares, a drop of 34.1% from the February 28th total of 2,172,080 shares. Based on an average trading volume of 1,766,483 shares, the short-interest ratio is currently 0.8 days. Approximately 0.1% of the shares of the stock are short sold.

Who are some of Novartis' key competitors?

Some companies that are related to Novartis include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co. (MRK), AbbVie (ABBV), Novo Nordisk (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Bayer (BAYRY), AstraZeneca (AZN), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Who are Novartis' key executives?

Novartis' management team includes the folowing people:

Dr. Vasant Narasimhan, Chief Exec. Officer (Age 42)
Mr. Harry Kirsch, Chief Financial Officer (Age 53)
Felix R. Ehrat, Group Gen. Counsel (Age 61)
Mr. Steven Baert, Head of HR (Age 44)
Mr. Richard Francis, CEO, Sandoz (Age 50)

Has Novartis been receiving favorable news coverage?

News coverage about NVS stock has trended somewhat positive on Wednesday, according to Accern. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novartis earned a daily sentiment score of 0.18 on Accern's scale. They also assigned headlines about the company an impact score of 46.03 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $76.42.

How big of a company is Novartis?

Novartis has a market capitalization of $179.83 billion and generates $49.11 billion in revenue each year. The company earns $7.70 billion in net income (profit) each year or $4.81 on an earnings per share basis. Novartis employs 121,597 workers across the globe.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]

MarketBeat Community Rating for Novartis (NVS)

Community Ranking:		2.3 out of 5 ( )
Outperform Votes:		315 (Vote Outperform)
Underperform Votes:		382 (Vote Underperform)
Total Votes:		697

MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Novartis (NYSE:NVS) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

10 Wall Street analysts have issued ratings and price targets for Novartis in the last 12 months. Their average twelve-month price target is $87.75, suggesting that the stock has a possible upside of 14.83%. The high price target for NVS is $91.00 and the low price target for NVS is $82.25. There are currently 3 sell ratings, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	1.80	1.78	2.00	2.07
Ratings Breakdown:	3 Sell Rating(s) 6 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	3 Sell Rating(s) 5 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	4 Sell Rating(s) 6 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	3 Sell Rating(s) 7 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$87.75	$87.75	$84.4050	$84.5240
Price Target Upside:	14.83% upside	1.00% upside	2.85% downside	1.68% upside

Novartis (NYSE:NVS) Consensus Price Target History

Price Target History for Novartis (NYSE:NVS)

Novartis (NYSE:NVS) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/20/2018	Deutsche Bank	Reiterated Rating	Neutral		Low
4/9/2018	JPMorgan Chase	Reiterated Rating	Neutral		Low
1/15/2018	UBS	Reiterated Rating	Neutral		Low
1/2/2018	Nord/LB	Reiterated Rating	Neutral		Medium
12/6/2017	Bank of America	Downgrade	Neutral -> Underperform		Low
10/25/2017	Barclays	Downgrade	Equal Weight -> Underweight		N/A
10/23/2017	Leerink Swann	Boost Price Target	Market Perform	$89.00 -> $91.00	N/A
8/9/2017	Cowen	Set Price Target	Hold	$90.00	Medium
7/26/2017	Morgan Stanley	Upgrade	Underweight -> Overweight		Low
7/5/2017	Credit Suisse Group	Downgrade	Neutral -> Underperform	$82.25	Medium
3/22/2017	Goldman Sachs	Reiterated Rating	Neutral		Low
3/9/2017	Liberum Capital	Initiated Coverage	Buy -> Buy		Low
3/7/2017	Societe Generale	Upgrade	Hold -> Buy	$73.82 -> $74.37	N/A
3/7/2017	BNP Paribas	Downgrade	Neutral -> Underperform		N/A
1/31/2017	Argus	Upgrade	Hold -> Buy		N/A
1/17/2017	Berenberg Bank	Downgrade	Buy -> Hold		N/A
10/16/2016	Jefferies Group	Reiterated Rating	Buy		N/A
10/10/2016	Chardan Capital	Lower Price Target	Buy	$95.00 -> $92.00	N/A
5/24/2016	Citigroup	Reiterated Rating	Neutral		N/A

(Data available from 4/25/2016 forward)

Novartis (NYSE:NVS) Earnings History and Estimates Chart

Earnings by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE:NVS) Earnings Estimates

2018 EPS Consensus Estimate: $5.47

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$1.24	$1.31	$1.28
Q2 2018	1	$1.34	$1.34	$1.34
Q3 2018	1	$1.35	$1.35	$1.35
Q4 2018	1	$1.50	$1.50	$1.50

Novartis (NYSE NVS) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/17/2018
4/19/2018	Q1	$1.25	$1.28	$12.4515 billion	$12.6940 billion	View	N/A
1/24/2018	n/a	$1.16	$1.20	$12.6464 billion	$12.9150 billion	View	Listen
10/24/2017	9/30/2017	$1.25	$1.29	$12.2102 billion	$12.4130 billion	View	N/A
7/18/2017	Q2 17	$1.16	$1.22	$12.2043 billion	$12.2420 billion	View	N/A
4/25/2017	3/31/2017	$1.10	$1.13	$11.5933 billion	$11.5390 billion	View	N/A
1/25/2017	Q416	$1.12	$1.12	$12.4407 billion	$12.3220 billion	View	N/A
10/25/2016	Q316	$1.19	$1.23	$12.24 billion	$12.1260 billion	View	Listen
7/19/2016	Q216	$1.18	$1.23	$12.33 billion	$12.47 billion	View	Listen
4/21/2016	Q116	$1.18	$1.17	$11.90 billion	$11.60 billion	View	Listen
1/27/2016	Q415	$1.18	$1.14	$12.64 billion	$12.52 billion	View	Listen
10/27/2015	Q315	$1.31	$1.27	$12.66 billion	$12.30 billion	View	Listen
7/21/2015	Q215	$1.20	$1.27	$12.45 billion	$12.70 billion	View	Listen
4/23/2015	Q115	$1.12	$1.33	$12.90 million	$11.9350 billion	View	N/A
1/27/2015	Q314	$1.13	$1.21	$14.68 billion	$14.63 billion	View	N/A
10/28/2014	Q3 2014	$1.29	$1.28	$14.1420 billion	$14.7040 billion	View	N/A
7/17/2014	Q214	$1.36	$1.36	$14.8283 billion	$14.6370 billion	View	N/A
4/24/2014	Q1 2014	$1.33	$1.31	$14.2526 billion	$14.0220 billion	View	N/A
1/29/2014	Q413	$1.27	$1.20	$15.16 billion	$15.0780 billion	View	N/A
10/22/2013	Q313	$1.31	$1.26	$14.28 billion	$14.34 billion	View	N/A
7/17/2013	Q213	$1.29	$1.30	$14.39 billion	$14.50 billion	View	N/A
4/24/2013	Q113	$1.28	$1.32	$14.02 million	$14.0160 billion	View	N/A
1/23/2013	Q412	$1.19	$1.27	$14.42 billion	$14.80 billion	View	N/A
10/25/2012		$1.34	$1.34			View	N/A
7/19/2012		$1.33	$1.38			View	N/A
4/24/2012		$1.30	$1.27			View	N/A
1/25/2012		$1.26	$1.23			View	N/A
10/25/2011		$1.45	$1.45			View	N/A
7/19/2011		$1.46	$1.48			View	N/A
4/19/2011		$1.30	$1.41			View	N/A
1/27/2011		$1.25	$1.14			View	N/A
10/21/2010	Q3 2010	$1.20	$1.36			View	N/A
7/15/2010	Q2 2010	$1.13	$1.20			View	N/A
1/26/2010	Q4 2009	$1.16	$1.01			View	N/A
10/22/2009	Q3 2009	$0.95	$0.92			View	N/A
4/23/2009	Q1 2009	$0.87	$0.87			View	N/A
1/28/2009	Q4 2008	$0.79	$0.66			View	N/A
10/20/2008	Q3 2008	$0.99	$0.92			View	N/A
7/17/2008	Q2 2008	$0.93	$0.99			View	N/A
1/23/2008	Q4 2007	$0.67	$0.41			View	N/A

(Earnings results data provided by Zacks Investment Research)

Novartis (NYSE:NVS) Dividend Information

Novartis pays an annual dividend of $1.91 per share, with a dividend yield of 2.50%. NVS's most recent annual dividend payment was Friday, March 3. Novartis pays out 39.71% of its earnings out as a dividend.

Most Recent Dividend:	3/3/2017
Annual Dividend:	$1.91
Dividend Yield:	2.50%
Dividend Growth:	-0.50% (3 Year Average)
Payout Ratio:	39.71% (Trailing 12 Months of Earnings) 36.17% (Based on This Year's Estimates) 34.05% (Based on Next Year's Estimates)

Dividend Payments by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE:NVS) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
1/27/2017	Annual	$2.3270		3/1/2017	3/3/2017	3/3/2017
2/1/2016	Annual	$2.34		2/24/2016	2/26/2016	2/26/2016
2/4/2014	annual	$2.7186	3.48%	2/27/2014	3/3/2014	3/11/2014
2/11/2013	annual	$2.53	3.71%	2/26/2013	2/28/2013	4/5/2013

(Data available from 1/1/2013 forward)

Novartis (NYSE NVS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 10.77%

Insider Trading History for Novartis (NYSE:NVS)

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE NVS) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
4/23/2018	Institutes For Biomed Novartis	Major Shareholder	Buy	766,666	$15.00	$11,499,990.00
7/5/2017	Bioventures Ltd Novartis	Major Shareholder	Buy	266,667	$15.00	$4,000,005.00
5/11/2016	Institutes For Biomed Novartis	Major Shareholder	Buy	277,777	$18.00	$4,999,986.00
2/17/2016	Bioventures Ltd Novartis	Major Shareholder	Buy	375,000	$8.00	$3,000,000.00
9/22/2014	Bioventures Ltd Novartis	Major Shareholder	Buy	325,000	$15.00	$4,875,000.00

(Data available from 1/1/2013 forward)

Novartis (NYSE NVS) News Headlines

Source:

Date	Headline
	Brainstorm Health: Health Care Prognosis, Novartis Eye App, Alcohol and Mouth Bacteria fortune.com - April 25 at 5:39 PM
	BRIEF-Novartis Launches Focalview App www.reuters.com - April 25 at 8:06 AM
	Novartis' digital drive continues with eye-disease app finance.yahoo.com - April 25 at 8:06 AM
	[$$] How Long Till the Final World Malaria Day? finance.yahoo.com - April 25 at 8:06 AM
	Novartis Q1 2018: Recent Sell-Off Seems Overdone seekingalpha.com - April 24 at 5:45 PM
	Is Biopharma Investing Too Much In Cancer R&D? finance.yahoo.com - April 24 at 5:45 PM
	Insider Buying: Novartis (NVS) Major Shareholder Purchases 766,666 Shares of Stock www.americanbankingnews.com - April 23 at 7:10 PM
	BRIEF-Novartis Institutes For Biomedical Research Reports 14.3 Pct Passive Stake In Surface Oncology www.reuters.com - April 23 at 5:22 PM
	Biotech Analysis Central Pharma News: J&J Scraps Antibiotic Program, Novartis Siponimod, GW Pharma's Major ... seekingalpha.com - April 23 at 8:06 AM
	Shire (SHPG) Turns Down Takeda's Third Buyout Proposition finance.yahoo.com - April 20 at 5:32 PM
	BRIEF-Novartis says EXPAND study shows siponimod's (Baf312) efficacy www.reuters.com - April 20 at 8:09 AM
	New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS ... globenewswire.com - April 20 at 8:09 AM
	Novartis (NVS) Earns Neutral Rating from Deutsche Bank www.americanbankingnews.com - April 20 at 6:38 AM
	Novartis (NVS) Misses Q1 EPS by 1c, Revenue Beats www.streetinsider.com - April 19 at 5:52 PM
	Novartis CEO feels heat on US generics, Cosentyx drop www.reuters.com - April 19 at 5:52 PM
	Novartis Stock Dips After Cosentyx Sales, Sandoz Generics Disappoint finance.yahoo.com - April 19 at 5:52 PM
	Novartis (NVS) Given a $77.00 Price Target at Cowen www.americanbankingnews.com - April 19 at 5:50 PM
	Novartis AG (ADR) Stock Drops on Q1 Earnings Miss investorplace.com - April 19 at 2:21 PM
	Novartis (NVS) Announces Earnings Results www.americanbankingnews.com - April 19 at 9:27 AM
	BRIEF-Novartis expects cost cuts, rising Entresto, Cosentyx sales to help meet 2018 op. profit targets www.reuters.com - April 19 at 8:04 AM
	UPDATE 1-Novartis confirms 2018 targets as Alcon recovery gains steam www.reuters.com - April 19 at 8:04 AM
	Novartis Q1 Profit Climbs, Misses Estimates; Backs FY18 View - Quick Facts www.nasdaq.com - April 19 at 8:04 AM
	Novartis confirms 2018 targets as Alcon recovery gains steam www.reuters.com - April 19 at 8:04 AM
	Novartis delivered a strong first quarter and acted to become a more focused medicines company globenewswire.com - April 19 at 8:04 AM
	[$$] Cancer and heart drugs boost Novartis sales finance.yahoo.com - April 19 at 8:04 AM
	New Novartis CEO feels heat on U.S. generics business finance.yahoo.com - April 19 at 8:04 AM
	Novartis: 1Q Earnings Snapshot finance.yahoo.com - April 19 at 8:04 AM
	Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver finance.yahoo.com - April 19 at 8:04 AM
	Novartis Earnings Top, But Key Drug, Generics Sales Disappoint finance.yahoo.com - April 19 at 8:04 AM
	Novartis to invest $100M to develop antimalarials www.marketwatch.com - April 18 at 8:05 AM
	Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria www.bloomberg.com - April 18 at 8:05 AM
	Form SC TO-T AveXis, Inc. Filed by: NOVARTIS AG www.streetinsider.com - April 17 at 6:08 PM
	Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab ... globenewswire.com - April 17 at 6:08 PM
	BRIEF-Novartis to invest $100 Mln over 5 years in anti-malarial drugs www.reuters.com - April 17 at 8:10 AM
	Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next ... globenewswire.com - April 17 at 8:10 AM
	Novartis tender offer for AveXis commences finance.yahoo.com - April 17 at 8:10 AM
	What Novartis Bought in AveXis www.fool.com - April 16 at 5:38 PM
	Did Novartis Overpay for AveXis? finance.yahoo.com - April 16 at 5:38 PM
	Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic ... globenewswire.com - April 16 at 8:04 AM
	Novartis to Post Q1 2018 Earnings of $1.24 Per Share, Jefferies Group Forecasts (NVS) www.americanbankingnews.com - April 16 at 1:19 AM
	Why GlaxoSmithKline's share price could be about to skyrocket www.fool.co.uk - April 15 at 8:53 AM
	Glaxo to Sell Rare Disease Gene Therapies to Private Biotech finance.yahoo.com - April 13 at 8:05 AM
	Novartis CEO: How To Create Cheaper Alternatives To The Most Expensive Drugs www.forbes.com - April 12 at 5:54 PM
	GlaxoSmithKline Buys Novartis’s Stake in Joint Venture finance.yahoo.com - April 12 at 5:54 PM
	Zacks: Brokerages Expect Novartis (NVS) to Post $1.33 EPS www.americanbankingnews.com - April 12 at 8:32 AM
	Incyte Has Diversified Its Revenues across Multiple Product Lines finance.yahoo.com - April 12 at 8:07 AM
	A Big Bet on Gene Therapy Is Just What Novartis AG (ADR) Stock Needs investorplace.com - April 12 at 7:51 AM
	Novartis (NVS) Set to Announce Earnings on Thursday www.americanbankingnews.com - April 12 at 1:25 AM
	Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis To Merge With Novartis And More feeds.benzinga.com - April 11 at 3:32 PM
	Novartis (NVS) Given a $90.00 Price Target at Cowen www.americanbankingnews.com - April 11 at 1:21 PM